血清层粘连蛋白γ2单体作为胰腺导管腺癌的一种新型诊断和预后标志物。

Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma.

作者信息

Terashima Takeshi, Nio Kouki, Koshikawa Naohiko, Ueno Makoto, Toyama Tadashi, Miyazawa Masaki, Hayashi Tomoyuki, Seki Akihiro, Nakagawa Hidetoshi, Iida Noriho, Yamada Shinya, Takatori Hajime, Shimakami Tetsuro, Yoshimura Toru, Yoshida Eisaku, Nakagawa Masatoshi, Seiki Motoharu, Yamashita Taro

机构信息

Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.

School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.

出版信息

BJC Rep. 2025 Jan 14;3(1):2. doi: 10.1038/s44276-024-00116-z.

DOI:10.1038/s44276-024-00116-z

PMID:39809945

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11733115/

Abstract

BACKGROUND

The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC.

METHODS

This study included two cohorts. Cohort 1 included 142 PDAC patients, 55 patients with intraductal papillary mucinous neoplasm (IPMN), and 46 healthy individuals. Cohort 2 included 518 PDAC patients. The medical records of patients were reviewed. Cut-off levels for LG2m were determined by receiver operating characteristic analysis.

RESULTS

In Cohort 1, serum LG2m levels were significantly higher in PDAC patients compared with healthy individuals (P < 0.001) and IPMN patients (P < 0.001). Comparing PDAC patients and health individuals, the optimal cut-off level of LG2m was 9.55 pg/mL and the sensitivity, specificity, and area under the curve were 0.89, 0.87, and 0.88, respectively. High sensitivity of LG2m in PDAC patients were confirmed in Cohort 2. The sensitivity and specificity of LG2m was higher than that of CEA and CA19-9. In patients treated with resection or chemotherapy, high serum LG2m level indicated a significantly shorter survival (P = 0.042 and P < 0.001, respectively).

CONCLUSIONS

LG2m may be a useful diagnostic and prognostic marker for PDAC.

摘要

背景

确定有效的诊断和预后生物标志物对于改善胰腺导管腺癌（PDAC）患者的治疗结果至关重要。我们探讨了血清层粘连蛋白γ2单体（LG2m）水平作为PDAC生物标志物的潜力。

方法

本研究包括两个队列。队列1包括142例PDAC患者、55例导管内乳头状黏液性肿瘤（IPMN）患者和46名健康个体。队列2包括518例PDAC患者。回顾了患者的病历。通过受试者工作特征分析确定LG2m的临界值水平。

结果

在队列1中，PDAC患者的血清LG2m水平显著高于健康个体（P < 0.001）和IPMN患者（P < 0.001）。比较PDAC患者和健康个体，LG2m的最佳临界值水平为9.55 pg/mL，敏感性、特异性和曲线下面积分别为0.89、0.87和0.88。在队列2中证实了LG2m在PDAC患者中的高敏感性。LG2m的敏感性和特异性高于癌胚抗原（CEA）和糖类抗原19-9（CA19-9）。在接受手术切除或化疗的患者中，高血清LG2m水平表明生存期显著缩短（分别为P = 0.042和P < 0.001）。